Artelo Biosciences, Inc.
ARTL
$7.16
-$0.15-2.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.89M | 1.81M | 1.28M | 995.00K | 1.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.79M | 3.09M | 3.15M | 2.38M | 3.81M |
| Operating Income | -2.79M | -3.09M | -3.15M | -2.38M | -3.81M |
| Income Before Tax | -4.17M | -3.12M | -3.22M | -2.37M | -3.78M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.17M | -3.12M | -3.22M | -2.37M | -3.78M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.17M | -3.12M | -3.22M | -2.37M | -3.78M |
| EBIT | -2.79M | -3.09M | -3.15M | -2.38M | -3.81M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -6.18 | -11.89 | -16.83 | -13.01 | -20.99 |
| Normalized Basic EPS | -2.81 | -7.43 | -10.52 | -8.13 | -13.24 |
| EPS Diluted | -6.18 | -11.89 | -16.83 | -13.01 | -20.99 |
| Normalized Diluted EPS | -2.81 | -7.43 | -10.52 | -8.13 | -13.24 |
| Average Basic Shares Outstanding | 674.00K | 262.30K | 191.30K | 182.30K | 180.00K |
| Average Diluted Shares Outstanding | 674.00K | 262.30K | 191.30K | 182.30K | 180.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |